SHUKRAPHARPharmaceuticals
Shukra Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹30.34
-3.42%
Current P/E139.49xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E118.5x17.7% above avg
⚠️
339.1% Premium to Industry
SHUKRAPHAR P/E 139.49x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2024 | ₹4.23 | ₹14 | 3.2x |
| 2023 | ₹0.66 | ₹3 | 4.7x |
| 2022 | ₹0.02 | ₹3 | 132.5x |
| 2021 | ₹0.01 | ₹2 | 333.7x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Shukra Pharmaceuticals Ltd Valuation
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) currently trades at 139.49x earnings. The Pharmaceuticals sector average PE is 31.77x. SHUKRAPHAR commands a premium, reflecting high growth expectations. Historically, SHUKRAPHAR has traded at an average PE of 118.5x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
15.90%
Dividend Yield
0.03%
More on Shukra Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.